Benitec Biopharma Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Jerel Banks
Chief executive officer
US$918.7k
Total compensation
| CEO salary percentage | 58.7% |
| CEO tenure | 6.1yrs |
| CEO ownership | n/a |
| Management average tenure | 6.1yrs |
| Board average tenure | 8.8yrs |
Recent management updates
Most Shareholders Will Probably Find That The Compensation For Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Is Reasonable
Nov 30
How Does Benitec Biopharma's (NASDAQ:BNTC) CEO Salary Compare to Peers?
Dec 02Recent updates
Most Shareholders Will Probably Find That The Compensation For Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Is Reasonable
Nov 30Benitec Biopharma prices of $18M securities offering
Sep 13Benitec GAAP EPS of -$2.23, revenue of $0.07M
Sep 02We're A Little Worried About Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Rate
Jan 13We Think Benitec Biopharma (NASDAQ:BNTC) Needs To Drive Business Growth Carefully
Sep 30Will Benitec Biopharma (NASDAQ:BNTC) Spend Its Cash Wisely?
May 12Benitec Bio secures $13M capital via equity offering
Apr 28Can Benitec Biopharma (NASDAQ:BNTC) Afford To Invest In Growth?
Jan 27How Does Benitec Biopharma's (NASDAQ:BNTC) CEO Salary Compare to Peers?
Dec 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$22m |
| Dec 31 2023 | n/a | n/a | -US$22m |
| Sep 30 2023 | n/a | n/a | -US$20m |
| Jun 30 2023 | US$919k | US$540k | -US$20m |
| Mar 31 2023 | n/a | n/a | -US$20m |
| Dec 31 2022 | n/a | n/a | -US$19m |
| Sep 30 2022 | n/a | n/a | -US$18m |
| Jun 30 2022 | US$800k | US$506k | -US$18m |
| Mar 31 2022 | n/a | n/a | -US$17m |
| Dec 31 2021 | n/a | n/a | -US$18m |
| Sep 30 2021 | n/a | n/a | -US$16m |
| Jun 30 2021 | US$1m | US$440k | -US$14m |
| Mar 31 2021 | n/a | n/a | -US$13m |
| Dec 31 2020 | n/a | n/a | -US$11m |
| Sep 30 2020 | n/a | n/a | -US$10m |
| Jun 30 2020 | US$632k | US$400k | -US$8m |
| Mar 31 2020 | n/a | n/a | -US$7m |
| Dec 31 2019 | n/a | n/a | -US$6m |
| Sep 30 2019 | n/a | n/a | -US$2m |
| Jun 30 2019 | US$615k | US$400k | US$3m |
| Mar 31 2019 | n/a | n/a | US$2m |
| Dec 31 2018 | n/a | n/a | US$2m |
| Sep 30 2018 | n/a | n/a | -US$3m |
| Jun 30 2018 | US$91k | n/a | -US$9m |
Compensation vs Market: Jerel's total compensation ($USD918.73K) is above average for companies of similar size in the US market ($USD683.22K).
Compensation vs Earnings: Jerel's compensation has increased whilst the company is unprofitable.
CEO
Jerel Banks (48 yo)
6.1yrs
Tenure
US$918,725
Compensation
Dr. Jerel A. Banks, Ph D., M.D., has been the Chief Executive Officer of Benitec Biopharma Inc. since June 26, 2018. Dr. Banks has been the Executive Chairman of the Board at Benitec Biopharma Inc. since O...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman & CEO | 6.1yrs | US$918.73k | no data | |
| Executive Director | 6.1yrs | US$469.46k | 0.28% $ 181.2k | |
| Head of Discovery & Founding Scientist | 9.1yrs | US$238.78k | no data | |
| Senior Vice President of Manufacturing | no data | no data | no data |
6.1yrs
Average Tenure
Experienced Management: BNTC's management team is seasoned and experienced (6.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman & CEO | 7.8yrs | US$918.73k | no data | |
| Executive Director | 7.9yrs | US$469.46k | 0.28% $ 181.2k | |
| Independent Non-Executive Director | 11.3yrs | US$65.78k | 0.56% $ 364.2k | |
| Independent Non-Executive Director | 18.4yrs | US$67.30k | 0.0032% $ 2.1k | |
| Independent Non-Executive Director | 4.3yrs | US$62.99k | 0% $ 0 | |
| Member of Hepatology Clinical Advisory Board | 8.8yrs | no data | no data | |
| Member of Hepatology Clinical Advisory Board | 8.8yrs | no data | no data | |
| Member of Hepatology Clinical Advisory Board | 8.8yrs | no data | no data | |
| Member of Scientific & Clinical Advisory Board | no data | no data | no data |
8.8yrs
Average Tenure
53yo
Average Age
Experienced Board: BNTC's board of directors are considered experienced (8.8 years average tenure).